title: Polymer therapy: a novel treatment to improve fat graft viability.
abstract: BACKGROUND
  Autologous fat grafting is currently undergoing a renaissance. However, fat grafts are limited by unpredictable survival. Poloxamers can act as tissue surfactants. These nonionic surfactants have been shown to stabilize the membranes of damaged cells and to protect against injury and apoptosis in numerous models. This study was designed to investigate the ability of poloxamers to protect harvested adipocytes and to increase fat graft survival.
  
  
  METHODS
  Lipoaspirate was obtained from surgical patients. Samples were washed in normal saline, centrifuged at 200 g, treated with various poloxamers or poloxamer components for 30 minutes, centrifuged at 200 g, and implanted into the flanks of nude mice in 1.0-cc, 1.0-g lobules. The grafts were explanted serially for 10 days and at 6 weeks. Endpoints were weight, apoptosis, cell viability, DNA content, and histology.
  
  
  RESULTS
  Grafts treated with poloxamers P188, F108, and F127 demonstrated increased graft survival by weight. Fat grafts treated with poloxamers L64 and P188 demonstrated improvement in cell viability, and those treated with poloxamers L64, P188, and F38 demonstrated improved histology. P188-treated grafts demonstrated a 50 percent reduction in apoptosis compared with saline-treated controls (p < 0.05) and an overall 72 percent survival by weight at 6 weeks. P188 demonstrated statistically significant improvement by weight, DNA content, histology, and cell viability (89 percent versus 33 percent).
  
  
  CONCLUSIONS
  The authors demonstrate that poloxamers, with membrane-sealing capability, can increase graft survival. Among these poloxamers, P188 demonstrated statistically significant improvement in apoptosis, graft survival by weight, cell viability, DNA content, and histology.
authors: Boston, Mass. From the Department of Surgery, Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital.
authors: Miguel A
authors: MA
authors: Medina
authors: John T
authors: JT
authors: Nguyen
authors: John C
authors: JC
authors: Kirkham
authors: Jeffery H
authors: JH
authors: Lee
authors: Michael C
authors: MC
authors: McCormack
authors: Mark A
authors: MA
authors: Randolph
authors: William G
authors: WG
authors: Austen
references: Coleman SR. Structural fat grafts: The ideal filler? Clin Plast Surg. 2001;28:111–119.
references: Giugliano C, Benitez S, Wisnia P, Sorolla JP, Acosta S, Andrades P. Liposuction and lipoinjection treatment for congenital and acquired lipodystrophies in children. Plast Reconstr Surg. 2009;124:134–143.
references: Gutowski KA; ASPS Fat Graft Task Force. Current applications and safety of autologous fat grafts: A report of the ASPS fat graft task force. Plast Reconstr Surg. 2009;124:272–280.
references: Lam SM, Glasgold RA, Glasgold MJ. Limitations, complications, and long-term sequelae of fat transfer. Facial Plast Surg Clin North Am. 2008;16:391–399, v.
references: Yamaguchi M, Matsumoto F, Bujo H, et al. Revascularization determines volume retention and gene expression by fat grafts in mice. Exp Biol Med (Maywood) 2005;230:742–748.
references: Gonzalez AM, Lobocki C, Kelly CP, Jackson IP. An alternative method for harvest and processing fat grafts: An in vitro study of cell viability and survival. Plast Reconstr Surg. 2007;120:285–294.
references: Medina MA III, Nguyen JT, McCormack MM, Randolph MA, Austen WG Jr. A high-throughput model for fat graft assessment. Lasers Surg Med. 2009;41:738–744.
references: Greenebaum B, Hannig J, Carrillo CS, et al. Poloxamer 188 prevents acute necrosis of adult skeletal muscle cells following high-dose irradiation. Burns 2004;30:539–547.
references: Lee RC, River LP, Pan FS, Ji L, Wollmann RL. Surfactant-induced sealing of electropermeabilized skeletal muscle membranes in vivo. Proc Natl Acad Sci USA. 1992;89:4524–4528.
references: Maskarinec SA, Wu G, Lee KY. Membrane sealing by polymers. Ann N Y Acad Sci. 2005;1066:310–320.
references: Khattak SF, Bhatia SR, Roberts SC. Pluronic F127 as a cell encapsulation material: Utilization of membrane-stabilizing agents. Tissue Eng. 2005;11:974–983.
references: Yi C, Pan Y, Zhen Y, et al. Enhancement of viability of fat grafts in nude mice by endothelial progenitor cells. Dermatol Surg. 2006;32:1437–1443.
references: Murphy AD, McCormack MC, Bichara DA, et al. Poloxamer 188 protects against ischemia-reperfusion injury in a murine hind-limb model. Plast Reconstr Surg. 2010;125:1651–1660.
references: Schaer GL, Hursey TL, Abrahams SL, et al. Reduction in reperfusion-induced myocardial necrosis in dogs by RheothRx injection (poloxamer 188 N.F.), a hemorheological agent that alters neutrophil function. Circulation 1994;90:2964–2975.
references: Schaer GL, Spaccavento LJ, Browne KF, et al. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction: Results of a randomized, double-blind, placebo-controlled trial. Circulation 1996;94:298–307.
references: Watanabe M, Okada T. Lysophosphatidylcholine-induced myocardial damage is inhibited by pretreatment with poloxamer 188 in isolated rat heart. Mol Cell Biochem. 2003;248:209–215.
references: Yasuda S, Townsend D, Michele DE, Favre EG, Day SM, Metzger JM. Dystrophic heart failure blocked by membrane sealant poloxamer. Nature 2005;436:1025–1029.
references: Birchenough SA, Rodeheaver GT, Morgan RF, Peirce SM, Katz AJ. Topical poloxamer-188 improves blood flow following thermal injury in rat mesenteric microvasculature. Ann Plast Surg. 2008;60:584–588.
references: Hannig J, Zhang D, Canaday DJ, et al. Surfactant sealing of membranes permeabilized by ionizing radiation. Radiat Res. 2000;154:171–177.
references: Merchant FA, Holmes WH, Capelli-Schellpfeffer M, Lee RC, Toner M. Poloxamer 188 enhances functional recovery of lethally heat-shocked fibroblasts. J Surg Res. 1998;140:131–140.
references: Serbest G, Horwitz J, Barbee K. The effect of poloxamer-188 on neuronal cell recovery from mechanical injury. J Neurotrauma 2005;22:119–132.
references: Marks JD, Pan CY, Bushell T, Cromie W, Lee RC. Amphiphilic, tri-block copolymers provide potent membrane-targeted neuroprotection. FASEB J. 2001;15:1107–1109.
references: Borgens RB, Bohnert D, Duerstock B, Spomar D, Lee RC. Subcutaneous tri-block copolymer produces recovery from spinal cord injury. J Neurosci Res. 2004;76:141–154.
references: Quinn M, Mukhida K, Sadi D, Hong M, Mendez I. Adjunctive use of the non-ionic surfactant Poloxamer 188 improves fetal dopaminergic cell survival and reinnervation in a neural transplantation strategy for Parkinson's disease. Eur J Neurosci. 2008;27:43–52.
references: Zhang Z, al-Rubeai M, Thomas CR. Effect of Pluronic F-68 on the mechanical properties of mammalian cells. Enzyme Microb Technol. 1992;14:980–983.
references: Tharmalingam T, Ghebeh H, Wuerz T, Butler M. Pluronic enhances the robustness and reduces the cell attachment of mammalian cells. Mol Biotechnol. 2008;39:167–177.
references: Ferguson RE, Cui X, Fink BF, Vasconez HC, Pu LL. The viability of autologous fat grafts harvested with the LipiVage system. Ann Plast Surg. 2008;60:594–597.
references: Suga H, Matsumoto D, Inoue K, et al. Numerical measurement of viable and nonviable adipocytes and other cellular components in aspirated fat tissue. Plast Reconstr Surg. 2008;122:103–114.
references: Lee RC, Despa F, Tang X, et al. Direct observation of the p188 mediated membrane sealing with atomic force microscopy. Mol Cell Biomech. 2006;3:185–186.
references: Maskarinec SA, Hannig J, Lee RC, Lee KY. Direct observation of poloxamer 188 insertion into lipid monolayers. Biophys J. 2002;82:1453–1459.
references: Wu G, Lee KY. Effects of poloxamer 188 on phospholipid monolayer morphology: An atomic force microscopy study. Langmuir 2009;25:2133–2139.
references: Agarwal J, Walsh A, Lee RC. Multimodal strategies for resuscitating injured cells. Ann N Y Acad Sci. 2005;1066:295–309.
references: Singh-Joy SD, McLain VC. Safety assessment of poloxamers 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, and 407, poloxamer 105 benzoate, and poloxamer 182 dibenzoate as used in cosmetics. Int J Toxicol. 2008;27(Suppl 2):93–128.